Table 4

Talimogene laherparepvec (T-VEC) as first-line therapy correlated with best overall response rates (complete response (CR), stable disease (SD), partial response (PR), progressive disease (PD))

Best overall response rate
TotalCRSDPRPD
T-VEC secondline43 (48.9%)15 (17.0%)5 (5.7%)8 (9.1%)15 (17.0%)
T-VEC firstline45 (51.1%)23 (26.1%)3 (3.4%)10 (11.4%)9 (10.2%)